| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CNCR.21967 |
| P698 | PubMed publication ID | 16721817 |
| P2093 | author name string | Tipu Nazeer | |
| Maroun Karam | |||
| Ameera Ali | |||
| Francis Nugent | |||
| Jomol Cyriac | |||
| Leon Novak | |||
| P2860 | cites work | Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL. | Q34762088 |
| Stage III follicular lymphoma: long-term follow-up and patterns of failure. | Q35552419 | ||
| The role of PET imaging in lymphoma | Q35880451 | ||
| Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas | Q35920204 | ||
| FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases | Q36019057 | ||
| Non-Hodgkin lymphoma: diagnosis and treatment | Q36224575 | ||
| Staging and classification of lymphoma | Q36228249 | ||
| Initial staging of lymphoma with positron emission tomography and computed tomography | Q36228259 | ||
| Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). | Q43695199 | ||
| Lymphoma: diagnosis, staging, natural history, and treatment strategies | Q46399648 | ||
| Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. | Q46443812 | ||
| Role of positron emission tomography in lymphoma | Q46443828 | ||
| A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma | Q46621429 | ||
| Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. | Q53444277 | ||
| Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type | Q73245475 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fluorine | Q650 |
| patient | Q181600 | ||
| positron emission tomography | Q208376 | ||
| P1104 | number of pages | 9 | |
| P304 | page(s) | 175-183 | |
| P577 | publication date | 2006-07-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. | |
| P478 | volume | 107 |
| Q54626611 | 18F-FDG PET/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation. |
| Q40543305 | 18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience |
| Q53227973 | 18F-Fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography in mucosa-associated lymphoid tissue lymphoma: variation in 18F-FDG avidity according to site involvement. |
| Q39385000 | 2-[18F]fludarabine, a novel positron emission tomography (PET) tracer for imaging lymphoma: a micro-PET study in murine models |
| Q44438293 | 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation. |
| Q39950688 | Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy? |
| Q38052458 | Advances in oncologic imaging: update on 5 common cancers |
| Q33575972 | Cellular density evaluation for malignant lymphoma using equivalent cross-relaxation rate imaging - initial experience |
| Q37220967 | Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma |
| Q58789840 | Comparison of Contrast-Enhanced Ultrasound and Positron Emission Tomography/Computed Tomography (PET/CT) in Lymphoma |
| Q48287153 | Complete metabolic response (CMR) in positron emission tomography-computed tomography (PET-CT) scans may have prognostic significance in patients with marginal zone lymphomas (MZL). |
| Q46016994 | Correlating metabolic activity with cellular proliferation in follicular lymphomas. |
| Q38187365 | Current role of FDG PET/CT in lymphoma |
| Q38232257 | Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis. |
| Q48736876 | Development of diffuse large B-cell lymphoma from follicular lymphoma of the duodenum: changes in endoscopic findings during a 6-year follow-up |
| Q26773194 | Diagnosis of follicular lymphoma of the gastrointestinal tract: A better initial diagnostic workup |
| Q42934424 | Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma |
| Q53157009 | Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma. |
| Q91813345 | Energy metabolism is co-determined by genetic variants in chronic lymphocytic leukemia and influences drug sensitivity |
| Q43792807 | Evaluating the place of 18-fluoro-2-deoxy-D-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphoma. |
| Q35080079 | FDG PET-CT in follicular lymphoma: a case-based evidence review |
| Q91414532 | FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma |
| Q53135049 | FDG PET/CT predictive role in follicular lymphoma. |
| Q33642244 | FDG-PET Scan: a new Paradigm for Follicular Lymphoma Management |
| Q41840128 | FDG-PET in Follicular Lymphoma Management |
| Q46656081 | FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma |
| Q37677620 | Gastrointestinal follicular lymphoma: review of the literature |
| Q53497334 | Importance of [18F]fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma. |
| Q91892387 | Late Gadolinium Enhancement Cardiac Magnetic Resonance Tissue Characterization for Cancer-Associated Cardiac Masses: Metabolic and Prognostic Manifestations in Relation to Whole-Body Positron Emission Tomography |
| Q37865544 | Magnetic resonance imaging of malignant lymphoma |
| Q37356247 | Medical management update: Non-Hodgkin lymphoma. |
| Q36693111 | Metabolism pathways in chronic lymphocytic leukemia |
| Q37624527 | Mucosa-associated lymphoid tissue lymphoma with unusual 18F-FDG hypermetabolism arising at the colorectal anastomosis |
| Q53468430 | PET for follicular lymphoma: a work in progress! |
| Q38794783 | PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma |
| Q38179303 | PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study |
| Q39243194 | PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia |
| Q40481449 | Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients. |
| Q46309065 | Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. |
| Q39414818 | Positron emission tomography of 64Cu-DOTA-Rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL. |
| Q90638540 | Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma |
| Q36911505 | Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma |
| Q35736289 | Radiation Dosimetry Study of [(89)Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography |
| Q34659176 | Recent advances in the diagnosis and therapy of Richter's syndrome |
| Q33781006 | Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas |
| Q39128047 | Recommendations for the management of adrenal incidentalomas: what is pertinent for radiologists? |
| Q47984316 | Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group |
| Q45344362 | Role of 18F-FDG PET-CT for evaluating the response to reduced-intensity conditioning allogeneic transplant in heavily pre-treated patients with chronic lymphocytic leukemia: preliminary results in nine patients |
| Q44207367 | Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma. |
| Q37240835 | Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. |
| Q44908024 | SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma |
| Q34506646 | SUVmax/THKmax as a biomarker for distinguishing advanced gastric carcinoma from primary gastric lymphoma |
| Q41856030 | Small lymphocytic lymphoma obscuring microscopic tonsillar squamous cell carcinoma: an unknown occurrence with a known primary |
| Q100526120 | Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989-2016 |
| Q53152573 | State-of-the-art PET/CT of the pancreas: current role and emerging indications. |
| Q28073262 | Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How |
| Q36663969 | The Value of PET/CT in Detecting Bone Marrow Involvement in Patients With Follicular Lymphoma |
| Q46638000 | The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. |
| Q53476118 | The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organiza |
| Q26851974 | Transformed follicular non-Hodgkin lymphoma |
| Q48354783 | Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter? |
| Q88123537 | Uptake of [18F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma |
| Q35569501 | Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma |
| Q38015946 | Value of 18FDG PET scan in staging of ocular adnexal lymphomas: a large single-center experience |
| Q47732077 | WB MRI and oncology: recent major advances. |
| Q38153086 | When should FDG-PET be used in the modern management of lymphoma? |
| Q53083275 | Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients. |
| Q38907077 | [18 F]-FDG PET/CT in the staging and management of indolent lymphoma: A prospective multicenter PET registry study |
Search more.